ANKTIVA ® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA product ImmunityBio’s 400,000 square foot GMP fill-finish facility in ...
Dunkirk’s state-of-the-art facility is expected to play a significant role in the production of a new cancer-fighting drug developed by ImmunityBio Inc. On Tuesday, the company announced in a news ...
DUNKIRK, N.Y. — ImmunityBio has filed a WARN notice with the New York state Department of Labor for two layoffs at its plant in Dunkirk. According to the notice, the California-based biopharmaceutical ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min ImmunityBio plans to use the ...
A monumental achievement for ImmunityBio, Inc., occurred earlier this week, leaving the door open for potential major benefits to the Dunkirk community. Earlier this week, the Food and Drug ...
As it continues construction, ImmunityBio noted in a quarterly regulatory filing that it believes governmental funding will assist in funding a portion of the further build-out in Dunkirk. As of March ...
A long-stalled pharmaceutical manufacturing project in Dunkirk may finally be moving toward a restart, with a revised agreement setting new financial terms, deadlines, and hiring expectations for ...
Over 400,000 square foot, state-of-the-art, finish-fill and lyophilization facility enables one billion doses of RNA and adjuvant vaccine production Newly constructed Current Good Manufacturing ...
Stocktwits on MSN
IBRX stock jumps after-hours: Bulls cheer 'unstoppable' global expansion amid US regulatory heat for Anktiva
ImmunityBio plans to present new Anktiva bladder-cancer data at the upcoming AUA meeting. ・The company said it will also provide updates on recombinant BCG research and efforts to improve BCG access.
It’s been an up-and-down several years at a state-funded, $200 million drug manufacturing plant in Dunkirk, a facility that – to date – still has not actually manufactured a drug.
Stocktwits on MSN
IBRX stock climbs: Founder says AI robot built to mass-produce cancer-killing immune cells ships this month
Founder Patrick Soon-Shiong said the company’s AI-powered immune cell manufacturing robot is already in production. ・The “world’s first” NK-cell manufacturing robot uses AI and machine learning to ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX) announced today that the drug substance (DS) has been completed and successfully qualified for “fill finish” (filling vials and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results